Advertisement

Pathology & Oncology Research

, Volume 21, Issue 1, pp 83–95 | Cite as

Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer

  • Wa Zhong
  • Zhong Yu
  • Jun Zhan
  • Tao Yu
  • Ying Lin
  • Zhong-Sheng Xia
  • Yu-Hong Yuan
  • Qi-Kui Chen
Research

Abstract

Identifying predictive biomarkers for colorectal cancer would facilitate diagnosis and treatment of the disease. This study aimed to investigate the association of the serological biomarkers CEA, CA19–9, CA125, CYFRA21–1 and CA72–4 with patient characteristics and disease outcomes in colorectal cancer. Patients (N = 373) with colorectal cancer were evaluated for the association of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 pre and post-surgery and at disease recurrence with demographics, disease characteristics including pathological types, degree of differentiation, invasion depth, abdominal lymph node metastasis, TMN stage, Dukes stage, location of cancer and metastasis, and disease outcomes. It was more common for a patient to express these markers prior to surgery and at disease recurrence than following surgery. Overall, the serum levels of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 were not associated with age, gender, pathological type and location of cancer (all P-values >0.05), but were associated with the poor tumor differentiation, higher tumor invasion, greater degree of abdominal lymph node metastasis, and higher TNM and Duke stage tumors (all P-values < 0.01). CEA expression was associated with older ages (median age 65 years). Multivariate analysis indicated that CEA was correlated with overall survival and none of the markers correlated with disease recurrence. The expression of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 was associated with specific disease characteristics which tended to indicated more advanced disease and disease recurrence consistent with these biomarkers being useful for detecting colorectal cancer.

Keywords

Colorectal cancer Cancer marker TNM stage Duke stage Overall survival 

Notes

Acknowledgments

This study was funded by the Science and technology and social development project of Guangdong Province (No.2012B031800030).

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Colorectal cancerfacts & figures: 2010–2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed: August 16 2013
  3. 3.
    Liu X, Cai H, Wang Y (2012) Prognostic significance of tumour markers in chinese patients with gastric cancer. ANZ J Surg. doi: 10.1111/j.1445-2197.2012.06287.x Google Scholar
  4. 4.
    McKeown E, Nelson DW, Johnson EK et al (2014) Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer 5(1):31–43PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Perkins GL, Slater ED, Sanders GK et al (2003) Serum tumor markers. Am Fam Physician 68(6):1075–1082PubMedGoogle Scholar
  6. 6.
    Goldberg EM, Simunovic LM, Drake SL et al (1989) Comparison of serum ca 19–9 and cea levels in a population at high risk for colorectal cancer. Hybridoma 8(5):569–575PubMedCrossRefGoogle Scholar
  7. 7.
    Bast RC Jr, Klug TL, St John E et al (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883–887PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang D, Yu M, Xu T et al (2013) Predictive value of serum cea, ca19–9 and ca125 in diagnosis of colorectal liver metastasis in chinese population. Hepatogastroenterology 60(126):1297–1301PubMedGoogle Scholar
  9. 9.
    Ohuchi N, Takahashi K, Matoba N et al (1989) Comparison of serum assays for tag-72, ca19–9 and cea in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19(3):242–248PubMedGoogle Scholar
  10. 10.
    Shitara M, Yoshioka H, Sakurabayashi I et al (1988) fundamental studies and the reference values of cancer associated antigen tag-72 (ca72–4). Rinsho Byori 36(10):1177–1181PubMedGoogle Scholar
  11. 11.
    Kobayashi H (1989) The clinical usefulness of serum ca72–4 analysis in patients with ovarian cancer. Nihon Sanka Fujinka Gakkai Zasshi 41(5):585–589PubMedGoogle Scholar
  12. 12.
    Guadagni F, Roselli M, Cosimelli M et al (1995) Ca 72–4 serum marker–a new tool in the management of carcinoma patients. Cancer Investig 13(2):227–238CrossRefGoogle Scholar
  13. 13.
    Kosacka M, Jankowska R (2009) Comparison of cytokeratin 19 expression in tumor tissue and serum cyfra 21–1 levels in non-small cell lung cancer. Pol Arch Med Wewn 119(1–2):33–37PubMedGoogle Scholar
  14. 14.
    Pang L, Wang J, Jiang Y et al (2013) Decreased levels of serum cytokeratin 19 fragment cyfra 21–1 predict objective response to chemotherapy in patients with non-small cell lung cancer. Exp Ther Med 6(2):355–360PubMedCentralPubMedGoogle Scholar
  15. 15.
    Pujol JL, Grenier J, Daures JP et al (1993) Serum fragment of cytokeratin subunit 19 measured by cyfra 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53(1):61–66PubMedGoogle Scholar
  16. 16.
    Holdenrieder S, Stieber P, Liska V et al (2012) Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 32(5):1971–1976PubMedGoogle Scholar
  17. 17.
    Wild N, Andres H, Rollinger W et al (2010) A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 16(24):6111–6121PubMedCrossRefGoogle Scholar
  18. 18.
    Kornek GV, Depisch D, Rosen HR et al (1992) Comparative analysis of ca72–4, ca195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol 118(4):318–320PubMedCrossRefGoogle Scholar
  19. 19.
    Posner MR, Mayer RJ (1994) The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 8(3):533–553PubMedGoogle Scholar
  20. 20.
    Ueda T, Shimada E, Urakawa T (1994) The clinicopathologic features of serum ca 19–9-positive colorectal cancers. Surg Today 24(6):518–525PubMedCrossRefGoogle Scholar
  21. 21.
    Filella X, Molina R, Grau JJ et al (1992) Prognostic value of ca 19.9 levels in colorectal cancer. Ann Surg 216(1):55–59PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Zheng CX, Zhan WH, Zhao JZ et al (2001) The prognostic value of preoperative serum levels of cea, ca19–9 and ca72–4 in patients with colorectal cancer. World J Gastroenterol 7(3):431–434PubMedGoogle Scholar
  23. 23.
    Streppel MM, Vincent A, Mukherjee R et al (2012) Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol 43(10):1755–1763PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Zhang D, Yu M, Xu T et al (2013) Predictive value of serum cea, ca19–9 and ca125 in diagnosis of colorectal liver metastasis in chinese population. Hepatogastroenterology 60(126):1301Google Scholar
  25. 25.
    Yang XQ, Chen C, Wang FB et al (2011) Preoperative serum carcinoembryonic antigen, carbohydrate antigen19–9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer. Asian Pac J Cancer Prev 12(5):1251–1256PubMedGoogle Scholar
  26. 26.
    Yang XQ, Li Y, Chen C et al (2011) Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. Med Oncol 28(3):789–795PubMedCrossRefGoogle Scholar
  27. 27.
    Forones NM, Tanaka M (1999) Cea and ca 19–9 as prognostic indexes in colorectal cancer. Hepatogastroenterology 46(26):905–908PubMedGoogle Scholar
  28. 28.
    Nakayama T, Watanabe M, Teramoto T et al (1997) Ca19–9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66(4):238–243PubMedCrossRefGoogle Scholar
  29. 29.
    Shimono R, Mori M, Akazawa K et al (1994) Immunohistochemical expression of carbohydrate antigen 19–9 in colorectal carcinoma. Am J Gastroenterol 89(1):101–105PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2014

Authors and Affiliations

  • Wa Zhong
    • 1
  • Zhong Yu
    • 1
  • Jun Zhan
    • 1
  • Tao Yu
    • 1
  • Ying Lin
    • 1
  • Zhong-Sheng Xia
    • 1
  • Yu-Hong Yuan
    • 1
  • Qi-Kui Chen
    • 1
  1. 1.Department of Gastroenterology, Sun Yat-Sen Memorial HospitalSun Yat-Sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations